PATENT CLAIM ANALYSIS

Application Number: 15768953
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["514", "275000"]

Abstract:
The invention provides a compound of Formula I, or its tautomer, mesomer, racemate, enantiomer, diastereoisomer or a mixture thereof, or a pharmaceutically acceptable salt or solvate of the compound of Formula I, its tautomer, mesomer, racemate, enantiomer, or diastereoisomer. Ring A, R 1 , R 2 , R 3  and R 4  are as defined in the specification. The invention further provides a method for preparing the compound of Formula I and their use in the manufacture of a medicament for the treatment of a cell proliferative disorder.

Claim (Index 15):
The method for treating a cell proliferative disorder according to  claim 14 , characterized in that, said method further comprises administering via an oral or parenteral route an additional biologically active substance to said patient, wherein, said biologically active substance includes, but not limited to anticancer agent, immunosuppressive agent and antiviral agent;\n preferably, said anticancer agent is selected from one or more of cyclophosphamide, ifosfamide, thiotepa, semustine, mechlorethamine hydrochloride, busulfan, chlorambucil, sarcolysine, nitrocaphane, formylmerphalan, carmustine, lomustine, altretamine, dibromannitol, cytarabine, fluorouracil, methotrexate, hydroxyurea, tegafur, meisoindigotin, mercaptopurine, cisplatin, carboplatin, oxaliplatin, actinomycin D, mitomycin, adriamycin, pingyangmycin, epirubicin, pirarubicin, daunorubicin, bleomycin, homoharringtonine and its derivatives, vincristine and its derivatives, hydroxycamptothecine and its derivatives, etoposide and its derivatives, vindesine and its derivatives, vinblastine and its derivatives, vinorelbine bitartrate, paclitaxel and its derivatives, colchicine and its derivatives, elemene and its derivatives, aminoglutethimide, tamoxifen, dexamethasone, dutasteride, flutamide, gonadorelin, leuprorelin acetate, letrozole, sunitinib, sorafenib, imatinib, gefitinib, erlotinib, vandetinib, pazopanib, lapatinib, canertinib, afatinib, mubritinib, dasatinib, neratinib, trastuzumab, pertuzumab, rituximab, panitumumab, bevacizumab, ipilimumab, ofatumumab, ramucirumab, everolimus, sirolimus and zotarolimus.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 91.0
- Lexical Diversity: 2.10204
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15303704', '14365497', '14425207', '15933371', '15736898']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8024189400164585
- 35 USC 102 Novelty (BERT): 0.5516127535505608
- Combined Prediction Score: 0.7773383213698688
- Mean Citation Score: 406.717282
- Max Citation Score: 413.9792
- Similarity Product: 270.94151820688245

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test